>>Aperçu des publications scientifiques du Prof. Anne PERETZ

Anne PERETZ

1: Cappelle S, Peretz A. [The secondary prevention of osteoporosis needs a multidisciplinary approach]. Rev Med Brux. 2015 Sep;36(4):302-6. French.
>PubMed

2: Lefèvre G, Meyer A, Launay D, Machelart I, DeBandt M, Michaud J, Tournadre A, Godmer P, Kahn JE, Behra-Marsac A, Timsit MA, Schleinitz N, Wendling D, Melac-Ducamp S, Boyer P, Peretz A, Lequerré T, Richez C, Stervinou-Wemeau L, Morell-Dubois S, Lambert M, Dubucquoi S, Wallaert B, Benveniste O, Flipo RM, Hatron PY, Sibilia J, Hachulla E, Hervier B; Club Rhumatismes, Inflammation. Seronegative polyarthritis revealing antisynthetase syndrome: a multicentre study of 40 patients. Rheumatology (Oxford). 2015 May;54(5):927-32. doi: 10.1093/rheumatology/keu404. Epub 2014 Oct 27.
>PubMed

3: Steels E, Peretz A, Vereecken P. Infliximab-induced acne: a new case and review of published reports. J Dermatolog Treat. 2009;20(1):59-60. doi: 10.1080/09546630802155073. Review.
>PubMed

4: Peretz A. [Inflammatory low back pain]. Rev Med Brux. 2007 Sep;28(4):290-3. French.
>PubMed

5: Fernandez-Lopez MJ, Wamen S, Karmali R, Peretz A, Gonzalez-Gay MA, Bentin J. Low back pain as presenting manifestation of giant cell arteritis associated to abdominal aortitis. Clin Exp Rheumatol. 2007 Jan-Feb;25(1 Suppl 44):S31-3.
>PubMed

6: Vander Cruyssen B, Van Looy S, Wyns B, Westhovens R, Durez P, Van den Bosch F, Mielants H, De Clerck L, Peretz A, Malaise M, Verbruggen L, Vastesaeger N, Geldhof A, Boullart L, De Keyser F. Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: attrition and long-term evolution of disease activity. Arthritis Res Ther. 2006;8(4):R112.
>PubMed

7: Vander Cruyssen B, Van Looy S, Wyns B, Westhovens R, Durez P, Van den Bosch F, Veys EM, Mielants H, De Clerck L, Peretz A, Malaise M, Verbruggen L, Vastesaeger N, Geldhof A, Boullart L, De Keyser F. DAS28 best reflects the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients: validation of the DAS28 score in patients under infliximab treatment. Arthritis Res Ther. 2005;7(5):R1063-71. Epub 2005 Jul 8.
>PubMed

8: Malonne H, Coffiner M, Fontaine D, Sonet B, Sereno A, Peretz A, Vanderbist F. Long-term tolerability of tramadol LP, a new once-daily formulation, in patients with osteoarthritis or low back pain. J Clin Pharm Ther. 2005 Apr;30(2):113-20.
>PubMed

9: Durez P, Van den Bosch F, Corluy L, Veys EM, De Clerck L, Peretz A, Malaise M, Devogelaer JP, Vastesaeger N, Geldhof A, Westhovens R. A dose adjustment in patients with rheumatoid arthritis not optimally responding to a standard dose of infliximab of 3 mg/kg every 8 weeks can be effective: a Belgian prospective study. Rheumatology (Oxford). 2005 Apr;44(4):465-8. Epub 2005 Feb 3.
>PubMed

10: Peretz A, Siderova V, Body JJ, Dumon JC, Rozenberg S, Fellemans C, Fuss M, Bergmann P; Interdisciplinary Group for the Study of Bone Diseases and Calcium metabolism (GIPOB). Response to alendronate in osteoporotic women previously treated with pamidronate. Maturitas. 2003 Feb 25;44(2):111-5.
>PubMed

11: Body JJ, Gaich GA, Scheele WH, Kulkarni PM, Miller PD, Peretz A, Dore RK, Correa-Rotter R, Papaioannou A, Cumming DC, Hodsman AB. A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab. 2002 Oct;87(10):4528-35.
>PubMed

12: Peretz A, Guillaume MP, Casper-Velu L. Uveitis management: a multidisciplinary approach to assess systemic involvement and side effects of treatments. Acta Clin Belg. 2002 Jun-Jul;57(3):142-7.
>PubMed

13: Guillaume MP, Hermanus N, Peretz A. Unusual localisation of chronic arthropathy in lumbar facet joints after parvovirus B19 infection. Clin Rheumatol. 2002 Aug;21(4):306-8.
>PubMed

14: Peretz A, Papadopoulos T, Willems D, Hotimsky A, Michiels N, Siderova V, Bergmann P, Neve J. Zinc supplementation increases bone alkaline phosphatase in healthy men. J Trace Elem Med Biol. 2001;15(2-3):175-8.
>PubMed

15: Servais G, Daens S, Guillaume MP, Cumps J, Duchateau J, Peretz A. Diagnostic specificities and sensitivities of anti dsDNA, anti membrane DNA and anti nucleosomes autoantibodies. Scand J Clin Lab Invest Suppl. 2001;235:61-7.
>PubMed

16: Peretz A. [COX-2 inhibitor non-steroidal anti-inflammatory drugs, myth or reality?]. Rev Med Brux. 2001 Sep;22(4):A377-80. Review. French.
>PubMed

17: Peretz A, Siderova V, Nève J. Selenium supplementation in rheumatoid arthritis investigated in a double blind, placebo-controlled trial. Scand J Rheumatol. 2001;30(4):208-12.
>PubMed

18: Dumarey N, Martin P, Jayankura M, Putz P, Verhas M, Peretz A. A 'made in one piece' skeleton in a 22-year-old man suffering from sickle cell anaemia. Clin Rheumatol. 2000;19(4):287-90.
>PubMed

19: Peretz A, Penaloza A, Mesquita M, Dratwa M, Verhas M, Martin P, de Maertelaer V, Bergmann P. Quantitative ultrasound and dual X-ray absorptiometry measurements of the calcaneus in patients on maintenance hemodialysis. Bone. 2000 Aug;27(2):287-92.
>PubMed

20: Cherifi S, Guillaume MP, Peretz A. Multidrug-resistant tuberculosis spondylitis. Acta Clin Belg. 2000 Jan-Feb;55(1):34-6.
>PubMed

21: Daens S, Peretz A, de Maertelaer V, Moris M, Bergmann P. Efficiency of quantitative ultrasound measurements as compared with dual-energy X-ray absorptiometry in the assessment of corticosteroid-induced bone impairment. Osteoporos Int. 1999;10(4):278-83.
>PubMed

22: Peretz A, De Maertelaer V, Moris M, Wouters M, Bergmann P. Evaluation of quantitative ultrasound and dual X-Ray absorptiometry measurements in women with and without fractures. J Clin Densitom. 1999 Summer;2(2):127-33.
>PubMed

23: Peretz A. [New NSAIDS: COX-1, COX-2, what about them?]. Rev Med Brux. 1998 Sep;19(4):A399-402. Review. French.
>PubMed

24: Peretz A. [Evaluation of the cost of non-hormonal treatment of osteoporosis]. Rev Med Brux. 1998 Sep;19(4):A204-7. French.
>PubMed

25: Rozenberg S, Barudy Vasquez J, Kroll M, Twagirayezu P, Vandromme J, Peretz A. [Pharmacoeconomics of menopause treatments: epidemiological data and hormonal and non-hormonal prescription attitude of Belgian gynecologists]. Rev Med Brux. 1998 Sep;19(4):A195-8. French.
>PubMed

26: Praet JP, Peretz A, Mets T, Rozenberg S. Comparative study of the intestinal absorption of three salts of calcium in young and elderly women. J Endocrinol Invest. 1998 Apr;21(4):263-7.
>PubMed

27: Peretz A, Body JJ, Dumon JC, Rozenberg S, Hotimski A, Praet JP, Moris M, Ham H, Bergmann P. Cyclical pamidronate infusions in postmenopausal osteoporosis. Maturitas. 1996 Aug;25(1):69-75.
>PubMed

28: Peretz A, Moris M, Willems D, Bergmann P. Is bone alkaline phosphatase an adequate marker of bone metabolism during acute corticosteroid treatment? Clin Chem. 1996 Jan;42(1):102-3.
>PubMed

29: Moris M, Peretz A, Tjeka R, Negaban N, Wouters M, Bergmann P. Quantitative ultrasound bone measurements: normal values and comparison with bone mineral density by dual X-ray absorptiometry. Calcif Tissue Int. 1995 Jul;57(1):6-10.
>PubMed

30: Peretz A. [Bone following the menopause]. Rev Med Brux. 1995 Jul-Aug;16(4):280-4. French.
>PubMed

31: Rozenberg S, Vandromme J, Aguillera A, Peretz A, Ham H. Clinical significance of heterogeneity of vertebral mineral density. Maturitas. 1995 Feb;21(2):147-51.
>PubMed

32: Quivy D, Nève J, Fontaine J, Wasowicz W, Famaey JP, Peretz A. Trace element status and inflammation parameters during chronic indomethacin treatment in adjuvant arthritic rats. Biol Trace Elem Res. 1995 Jan-Mar;47(1-3):209-18.
>PubMed

33: Nève J, Wasowicz W, Quivy D, Parij N, Van Gossum A, Peretz A. Lipid peroxidation assessed by serum thiobarbituric acid reactive substances in healthy subjects and in patients with pathologies known to affect trace element status. Biol Trace Elem Res. 1995 Jan-Mar;47(1-3):147-53.
>PubMed

34: Rozenberg S, Vandromme J, Kroll M, Praet JP, Peretz A, Ham H. Overview of the clinical usefulness of bone mineral measurements in the prevention of postmenopausal osteoporosis. Int J Fertil Menopausal Stud. 1995 Jan-Feb;40(1):12-24. Review.
>PubMed

35: Rozenberg S, Vandromme J, Neve J, Aguilera A, Muregancuro A, Peretz A, Kinthaert J, Ham H. Precision and accuracy of in vivo bone mineral measurement in rats using dual-energy X-ray absorptiometry. Osteoporos Int. 1995 Jan;5(1):47-53.
>PubMed

36: Peretz A, Cantinieaux B, Nève J, Siderova V, Fondu P. Effects of zinc supplementation on the phagocytic functions of polymorphonuclears in patients with inflammatory rheumatic diseases. J Trace Elem Electrolytes Health Dis. 1994 Dec;8(3-4):189-94.
>PubMed

37: Rozenberg S, Ham H, Peretz A, Robyn C, Degueldre M. Bone mineral content of women with uterine fibromyomas. Int J Fertil Menopausal Stud. 1994 Mar-Apr;39(2):77-80.
>PubMed

38: Wasowicz W, Nève J, Peretz A. Optimized steps in fluorometric determination of thiobarbituric acid-reactive substances in serum: importance of extraction pH and influence of sample preservation and storage. Clin Chem. 1993 Dec;39(12):2522-6.
>PubMed

39: Rozenberg S, Gevers R, Peretz A, Vandromme J, Robyn C, Ham H. Decrease of bone mineral density during estrogen substitution therapy. Maturitas. 1993 Nov;17(3):205-10.
>PubMed

40: Peretz A, Nève J, Jeghers O, Pelen F. Zinc distribution in blood components, inflammatory status, and clinical indexes of disease activity during zinc supplementation in inflammatory rheumatic diseases. Am J Clin Nutr. 1993 May;57(5):690-4.
>PubMed

41: Rozenberg S, Peretz A, Praet JP, Vandromme J, Ham H. Bone mineral density measured by dual photon and dual energy X-ray absorptiometry: a problem of accuracy. Nucl Med Commun. 1993 Mar;14(3):189-91.
>PubMed

42: Neve J, Hanocq M, Peretz A, Abi Khalil F, Pelen F. [Some factors influencing the bioavailability of zinc in oral pharmaceutical dosage forms]. J Pharm Belg. 1993 Jan-Feb;48(1):5-11. French.
>PubMed

43: Peretz A. [Osteocalcin, marker of bone metabolism]. Bull Mem Acad R Med Belg. 1993;148(1-2):90-6; discussion 97-9. French.
>PubMed

44: Rozenberg S, Vandromme J, Peretz A, Praet JP, Robyn C, Ham H. Time related bias in longitudinal studies using dual photon absorptiometry. J Endocrinol Invest. 1992 Dec;15(11):835-7.
>PubMed

45: Praet JP, Peretz A, Rozenberg S, Famaey JP, Bourdoux P. Risk of osteoporosis in men with chronic bronchitis. Osteoporos Int. 1992 Sep;2(5):257-61.
>PubMed

46: Peretz AM, Dhaene MM, Drowart A, Kinnaert P, Vertongen FM, Bourdoux PP. Evolution of osteocalcin, alkaline phosphatase and parathyroid hormone after parathyroidectomy in patients receiving chronic maintenance hemodialysis. J Rheumatol. 1992 Mar;19(3):411-5.
>PubMed

47: Fontaine J, Neve J, Peretz A, Famaey JP. Effects of acute prednisolone administration on plasma and liver copper in rats with adjuvant arthritis. Biol Trace Elem Res. 1992 Jan-Mar;32:355-60.
>PubMed

48: Nève J, Hanocq M, Peretz A, Khalil FA, Pelen F. Absorption and metabolism of oral zinc gluconate in humans in fasting state, during, and after a meal. Biol Trace Elem Res. 1992 Jan-Mar;32:201-12.
>PubMed

49: Peretz A, Nève J, Jeghers O, Leclercq N, Praet JP, Vertongen F, Famaey JP. Interest of zinc determination in leucocyte fractions for the assessment of marginal zinc status. Clin Chim Acta. 1991 Nov 9;203(1):35-46.
>PubMed

50: Peretz A. [Cortisone-induced osteoporosis: from physiopathogenesis to treatment]. Rev Med Brux. 1991 Oct;12(8):321-8. Review. French.
>PubMed

51: Nève J, Hanocq M, Peretz A, Abi Khalil F, Pelen F, Famaey JP, Fontaine J. Pharmacokinetic study of orally administered zinc in humans: evidence for an enteral recirculation. Eur J Drug Metab Pharmacokinet. 1991 Oct-Dec;16(4):315-23.
>PubMed

52: Peretz A, Muller G, Praet JP, Ham H, Famaey JP. Oesophageal involvement in rheumatoid arthritis patients: a study with oesophageal radionuclide transit using 81Krm. Nucl Med Commun. 1991 Oct;12(10):901-6.
>PubMed

53: Fontaine J, Nève J, Peretz A, Capel P, Famaey JP. Effects of acute and chronic prednisolone treatment on serum zinc levels in rats with adjuvant arthritis. Agents Actions. 1991 Jul;33(3-4):247-53.
>PubMed

54: Peretz A, Nève J, Desmedt J, Duchateau J, Dramaix M, Famaey JP. Lymphocyte response is enhanced by supplementation of elderly subjects with selenium-enriched yeast. Am J Clin Nutr. 1991 May;53(5):1323-8.
>PubMed

55: Peretz A, Nève J, Duchateau J, Siderova V, Huygen K, Famaey JP, Carpentier YA. Effects of selenium supplementation on immune parameters in gut failure patients on home parenteral nutrition. Nutrition. 1991 May-Jun;7(3):215-21.
>PubMed

56: Peretz AM, Nève JD, Famaey JP. Selenium in rheumatic diseases. Semin Arthritis Rheum. 1991 Apr;20(5):305-16. Review.
>PubMed

57: Rozenberg S, Ham H, Peretz A, Caufriez A, Bosson D, Robyn C. Choice of parameter for expressing bone mineralization. Nucl Med Commun. 1991 Mar;12(3):189-95.
>PubMed

58: Fontaine J, Peretz A, Neve J, Pelen F, Famaey JP. Effects of chronic prednisolone administration on plasma copper in rats with adjuvant arthritis. Int J Tissue React. 1991;13(6):295-8.
>PubMed

59: Rozenberg S, Ham H, Bosson D, Peretz A, Robyn C. Age, steroids and bone mineral content. Maturitas. 1990 Jun;12(2):137-43.
>PubMed

60: Peretz A, Neve J, Famaey JP. [Metabolic disorders of essential trace elements related to rheumatic disorders]. Rev Med Brux. 1990 Jan-Feb;11(1-2):8-15. French.
>PubMed

61: Peretz A, Neve J, Famaey JP. Effects of chronic and acute corticosteroid therapy on zinc and copper status in rheumatoid arthritis patients. J Trace Elem Electrolytes Health Dis. 1989 Jun;3(2):103-8.
>PubMed

62: Peretz A, Praet JP, Rozenberg S, Bosson D, Famaey JP, Bourdoux P. Osteocalcin and bone mineral content in rheumatoid arthritis. Clin Rheumatol. 1989 Mar;8(1):42-8.
>PubMed

63: Peretz A, Praet JP, Bosson D, Rozenberg S, Bourdoux P. Serum osteocalcin in the assessment of corticosteroid induced osteoporosis. Effect of long and short term corticosteroid treatment. J Rheumatol. 1989 Mar;16(3):363-7.
>PubMed

64: Zamurovic D, Andry G, Lemort M, Dagnelie J, Peretz A, Dourov N, Mayer R, Famaey JP. Concomitant osteitis fibrosa cystica and ameloblastoma of the mandible. J Rheumatol. 1989 Mar;16(3):397-401.
>PubMed

65: Neve J, Vertongen F, Peretz A, Carpentier YA. [Usual values of selenium and glutathione peroxidase in a Belgian population]. Ann Biol Clin (Paris). 1989;47(3):138-43. French.
>PubMed

66: Fontaine J, Neve J, Peretz A, Pelen F, Famaey JP. Comparison of effects of chronic inflammation and long-term prednisolone administration on zinc metabolism in rats. Int J Tissue React. 1989;11(5):253-9.
>PubMed

67: Rozenberg S, Bosson D, Peretz A, Caufriez A, Robyn C. Serum levels of gonadotrophins and steroid hormones in the post-menopause and later life. Maturitas. 1988 Oct;10(3):215-24.
>PubMed

68: Nève J, Fontaine J, Peretz A, Famaey JP. Changes in zinc, copper and selenium status during adjuvant-induced arthritis in rats. Agents Actions. 1988 Aug;25(1-2):146-55.
>PubMed

69: Peretz A, Neve J, Vertongen F, Famaey JP, Molle L. Selenium status in relation to clinical variables and corticosteroid treatment in rheumatoid arthritis. J Rheumatol. 1987 Dec;14(6):1104-7.
>PubMed

!Données extraites de PubMed et filtrées pour limiter les risques d'homonymie. Vous pouvez supprimer le filtre "Brugmann" afin d'élargir les résultats.

>>Consulter la fiche d'identité du Prof. Anne PERETZ.